Home › Research › Risk factors
BACE1 as an early biomarker and its relevance to risk factors for Alzheimer’s disease
Masuo Ohno. Brain Research Bulletin, 2025-07-22
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
While the β-secretase BACE1 is responsible for the rate-limiting initial step to generate amyloid-β (Aβ) peptides, BACE1 inhibitor clinical trials have been halted due to a lack of efficacy and/or safety concerns at symptomatic/prodromal stages of Alzheimer's disease (AD). These trials were often targeted at high levels of BACE1 inhibition (>70 %) and ended up with signs of mild cognitive worsening instead of expected improvement. BACE1 concentration and activity are elevated in the cerebrospinal fluid and plasma/serum as well as brains of patients with mild cognitive impairment and AD dementia. Interestingly, recent evidence suggests that these fluid-based biomarkers reflective of BACE1 elevation may be associated with yet asymptomatic pathological changes in preclinical AD populations who are at high-risk for developing AD. Consistent with these findings, it has been demonstrated that exposures to major environmental and genetic risks such as diabetes, sleep disturbances, seizure, vascular disorders, stress, apolipoprotein E4, etc. converge on BACE1 elevation in humans and animal models, which may contribute to triggering sporadic AD. Moreover, vicious cycles exist between BACE1/Aβ elevations and certain prognostic conditions, further accelerating disease progression. Conversely, protective factors for AD are associated with reduced BACE1 level/activity. This review provides an overview of BACE1 alterations as common responses to a broad battery of AD risk and protective factors. The findings validate BACE1 as a biomarker for preclinical AD status that may be useful for earlier diagnosis and identifying subpopulations of individuals under AD risks who would benefit from preventive low-dose BACE1 inhibitor treatment with a higher probability.
What this study adds
Evidence grade: Low
This review reports that BACE1 levels are elevated in the cerebrospinal fluid, blood, and brains of people with mild cognitive impairment and Alzheimer's dementia, and may also be associated with asymptomatic changes in people at high risk. It notes that BACE1 inhibitor trials were halted due to lack of efficacy or safety concerns, and that many environmental and genetic risk factors converge on BACE1 elevation.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ohno, M. (2025). BACE1 as an early biomarker and its relevance to risk factors for Alzheimer’s disease. Brain Research Bulletin. https://doi.org/10.1016/j.brainresbull.2025.111475
Vancouver
Ohno M. BACE1 as an early biomarker and its relevance to risk factors for Alzheimer’s disease. Brain Research Bulletin. 2025. doi:10.1016/j.brainresbull.2025.111475. PMID: 40706761.
BibTeX
@article{ohno2025-40706761,
author = {Ohno, Masuo},
title = {{BACE1 as an early biomarker and its relevance to risk factors for Alzheimer’s disease}},
journal = {Brain Research Bulletin},
year = {2025},
doi = {10.1016/j.brainresbull.2025.111475},
pmid = {40706761},
url = {https://doi.org/10.1016/j.brainresbull.2025.111475}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Interestingly, recent evidence suggests that these fluid-based biomarkers reflective of BACE1 elevation may be associated with yet asymptomatic pathological changes in preclinical AD populations who are at high-risk for developing AD.
- Consistent with these findings, it has been demonstrated that exposures to major environmental and genetic risks such as diabetes, sleep disturbances, seizure, vascular disorders, stress, apolipoprotein E4, etc. converge on BACE1 elevation in humans and animal models, which may contribute to triggering sporadic AD.
- Conversely, protective factors for AD are associated with reduced BACE1 level/activity.
Why it matters
This review reports that BACE1 levels are elevated in the cerebrospinal fluid, blood, and brains of people with mild cognitive impairment and Alzheimer's dementia, and may also be associated with asymptomatic changes in people at high risk. It notes that BACE1 inhibitor trials were halted due to lack of efficacy or safety concerns, and that many environmental and genetic risk factors converge on BACE1 elevation.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Evidence strengthLow
How this study scored 39/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Brain Research Bulletin) |
| Journal's citation record | 2 / 4 | Brain Research Bulletin: journal h-index 203 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 10 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 5.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 1 / 4 | Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Masuo Ohno: h-index 42 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Nathan Kline Institute for Psychiatric Research: institution h-index 426 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40706761) |
| Free to read | 2 / 2 | Free to read |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.brainresbull.2025.111475
- PubMed: 40706761
- Original source →
- Free full text: Brain Research Bulletin →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 29.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Risk factors from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.